Apogee Therapeutics (APGE) Income from Continuing Operations (2022 - 2026)
Apogee Therapeutics (APGE) reported Income from Continuing Operations of 74111000.0 for Q1 2026, down 33.92% year-over-year from 112156551.78 in Q1 2025, and down 6.81% quarter-over-quarter from 69387000.0 in Q4 2025.
Apogee Therapeutics (APGE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has 5 years of Income from Continuing Operations data on file, last reported at 74111000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 74111000.0, down 33.92% year-over-year; the trailing twelve-month figure through Mar 2026 was 274615000.0 (down 33.7% YoY), and the FY2025 annual result was 255843000.0, down 40.46% from the prior year.
- Income from Continuing Operations fell to 74111000.0 in Q1 2026 per APGE's latest filing, from 69387000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 43631000.0 in Q4 2023 and troughed at 74111000.0 in Q1 2026.
- A 5-year average of 34196312.5 and a median of 32955000.0 in 2024 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 409.46% in 2023 and fell as far as 939.92% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 14099000.0 in 2022, then soared by 409.46% to 43631000.0 in 2023, then tumbled by 254.06% to 67218000.0 in 2024, then decreased by 3.23% to 69387000.0 in 2025, then fell by 6.81% to 74111000.0 in 2026.
- Business Quant data shows APGE's Income from Continuing Operations at 74111000.0 in Q1 2026, 69387000.0 in Q4 2025, and 65021000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Apogee Therapeutics | 6.29 Bn | 5.23 Bn | - | -74.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.11 Mn |
| Dec 31, 2025 | -69.39 Mn |
| Sep 30, 2025 | -65.02 Mn |
| Jun 30, 2025 | -66.10 Mn |
| Mar 31, 2025 | -55.34 Mn |
| Dec 31, 2024 | -67.22 Mn |
| Sep 30, 2024 | -49.02 Mn |
| Jun 30, 2024 | -33.82 Mn |
| Mar 31, 2024 | -32.09 Mn |
| Dec 31, 2023 | 43.63 Mn |
| Sep 30, 2023 | -20.84 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.53 Mn |
| Dec 31, 2022 | -14.10 Mn |
| Sep 30, 2022 | -10.51 Mn |
| Jun 30, 2022 | -1.82 Mn |